Methods, assays and kits for cancer diagnosis and screening utilizing glycan-binding and glycan epitopes

A method for detecting, diagnosing or monitoring breast cancer in a patient comprising obtaining a test sample from a patient and detecting the presence of antiglycan antibodies:

• (a) against at least one of the glycans listed in Table 8 and 10;
• or
• (b) against at least one of the glycans listed in Table 8.

A method for facilitating the diagnosis of IDC in a patient comprising obtaining a test sample from a patient and detecting the presence of antiglycan autoantibodies against at least one of the glycans listed in Table 10.

A method for detecting, diagnosing or monitoring ovarian cancer in a patient comprising obtaining a test sample from a patient and detecting the presence of antiglycan autoantibodies against at least one of the glycans listed in Table 12.

A method of detecting or monitoring cancer in a patient comprising measuring at least one antiglycan binding profile of a test sample from said patient and comparing the measured profile with a profile of normal patient or profile of a patient with a family history of cancer, wherein a substantial difference in the test sample profile versus the normal or history of cancer is indicative of cancer.

A kit for diagnosing or monitoring cancer in an individual wherein the antiglycan binding profile of a test sample from said individual is determined and comparing the measured profile with a profile of normal patient or profile of a patient with a family history of cancer, wherein said kit comprises an array of glycan molecules selected from the glycans set out in Tables 6, 8, 10 and 12.

A kit for diagnosing or monitoring lung cancer in an individual wherein the antiglycan binding profile of a test sample from said individual is determined and comparing the measured profile with a profile of normal patient or profile of a patient with a family history of cancer or a smoker, wherein said kit comprises:

• (a) one or more glycan molecules selected from the glycans set out in Table 6;
• or
• (b) an array of glycan molecules selected from the glycans set out in Table 6.

A kit for diagnosing or monitoring ovarian cancer in an individual wherein the antiglycan binding profile of a test sample from said individual is determined and comparing the measured profile with a profile of normal patient or profile of a patient with a family history of cancer, wherein said kit comprises:

• (a) one or more glycan molecules selected from the glycans set out in Table 12;
• or
• (b) an array of glycan molecules selected from the glycans set out in Table 12 and Table 13.

A method of detecting or monitoring mesothelioma in a patient comprising measuring at least one antiglycan binding profile of a test sample from said patient and comparing the measured profile with a profile of normal patient or profile of a patient exposed to asbestos, wherein a substantial difference in the test sample profile versus the normal or asbestos exposed profiles is indicative of mesothelioma.

A kit for diagnosing or monitoring mesothelioma in an individual wherein the antiglycan binding profile of a test sample from said individual is determined and comparing the measured profile with a profile of normal patient or profile of a patient exposed to asbestos, wherein said kit comprises one or more glycan molecules selected from the glycans set out in Table 15.